Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine

Neuropsychopharmacology

Volumn 28, Issue 7, 2003, Pages 1227-1234

  Flores, Cecilia ^a,b   Coyle, Joseph T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Clozapine; Glutamate carboxypeptidase II; Haloperidol; N acetyl aspartyl glutamate; Phencyclidine; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PHENCYCLIDINE; PSYCHEDELIC AGENT; CARBOXYPEPTIDASE; DOPAMINE RECEPTOR BLOCKING AGENT; ENZYME INHIBITOR; GLUTAMATE CARBOXYPEPTIDASE II; SEROTONIN ANTAGONIST;

ARTICLE; BRAIN CORTEX; ENZYME ACTIVITY; ENZYME REGULATION; HIPPOCAMPUS; LIMBIC SYSTEM; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; UPREGULATION; ANIMAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; ENZYMOLOGY; MALE; METABOLISM; METHODOLOGY; PHYSIOLOGY; RADIOASSAY; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARBOXYPEPTIDASES; CLOZAPINE; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; GLUTAMATE CARBOXYPEPTIDASE II; HALOPERIDOL; HIPPOCAMPUS; MALE; PHENCYCLIDINE; PREFRONTAL CORTEX; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS;

EID: 0042924149     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300129     Document Type: Article

References (67)

1. Adams B, Moghaddam B (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18: 5545-5554.
2. Arvanov VL, Wang RY (1999). Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther 289: 1000-1006.
3. Bal A, Bachelot T, Savasta M, Manier M, Verna JM, Benabid AL et al (1994). Evidence for dopamine D2 receptor mRNA expression by striatal astrocytes in culture: in situ hybridization and polymerase chain reaction studies. Brain Res Mol Brain Res 23: 204-212.
4. Benes FM (2000). Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 31: 251-269.
5. Berger UV, Carter RE, McKee M, Coyle JT (1995). N-acetylated alpha-linked acidic dipeptidase is expressed by non-myelinating Schwann cells in the peripheral nervous system. J Neurocytol 24: 99-109.
6. Berger UV, Luthi-Carter R, Passani LA, Elkabes S, Black I, Konradi C et al (1999). Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J Comp Neurol 415: 52-64.
7. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF et al (2001). The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry 49: 39-46.
8. Bertolino A, Esposito G, Callicott JH, Mattay VS, Van Horn JD, Frank JA et al (2000). Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am J Psychiatry 157: 26-33.
9. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT et al (1996). Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry 153: 1554-1563.
10. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997). Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154: 805-811.
11. Bunney WE, Bunney BG (2000). Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res Brain Res Rev 31: 138-146.
12. Carlsson M, Carlsson A (1990). Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272-276.
13. Carter RE, Feldman AR, Coyle JT (1996). Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 93: 749-753.
14. Coyle JT (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 3: 241-253.
15. Coyle JT (1997). The nagging question of the function of N-acetylasparylglutamate. Neurobiol Dis 4: 231-238.
16. Coyle JT, Schwarcz R (2000). Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry 57: 90-93.
17. Deicken RF, Pegues M, Amend D (1999). Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia. Schizophr Res 37: 217-223.
18. Greene RW, Bergeron R, Coyle JT (1999). N-acetylaspartylglutamate antagonizes the NMDA receptor function in the CA1 area of the hippocampus. Soc Neurosci Abstr 25: 203.
19. Greene R, Bergeron R, McCarley R, Coyle JT, Grunze H (2000b). Short-term and long-term effects of N-methyl-D-aspartate receptor hypofunction. Arch Gen Psychiatry 57: 1180-1181.
20. Greene RW, Bergeron R, Tsai G, Coyle JT (2000a). Antagonism of the NMDA receptor function by NAAG is not a result of desensitization. Soc Neurosci Abstr 26.
21. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW et al (1996). NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 16: 2034-2043.
22. 2+ channels. Neurochem Int 32: 153-162.
23. Heckers S, Rauch SL, Goff D, Savage CR, Schacter DL, Fischman AJ et al (1998). Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1: 318-323.
24. Hirst WD, Cheung NY, Rattray M, Price GW, Wilkin GP (1998). Cultured astrocytes express messenger RNA for multiple serotonin receptor subtypes, without functional coupling of 5-HT1 receptor subtypes to adenylyl cyclase. Brain Res Mol Brain Res 61: 90-99.
25. Hosli E, Hosli L (1993). Receptors for neurotransmitters on astrocytes in the mammalian central nervous system. Prog Neurobiol 40: 477-506.
26. Hosli E, Hosli L (2000). Colocalization of neurotransmitter receptors on astrocytes in explant cultures of rat CNS. Neurochem Int 36: 301-311.
27. Knable MB, Weinberger DR (1997). Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 11: 123-131.
28. Krystal JH, Belger A, D'Souza DC, Anand A, Charney DS, Aghajanian GK et al (1999). Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology 21: S143-S157.
29. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995). Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6: 869-872.
30. Lieberman JA (1993). Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br J Psychiatry (Suppl): 7-18.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951). Protein measurement with Folin phenol reagent. J Biol Chem 193: 265-275.
32. Mathe JM, Nomikos GG, Schilstrom B, Svensson TH (1998). Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res 51: 583-592.
33. Meltzer HY (1991). The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263-287.
34. Meyerhoff JL, Carter RE, Yourick DL, Slusher BS, Coyle JT (1992). Genetically epilepsy-prone rats have increased brain regional activity of an enzyme which liberates glutamate from N-acetyl-aspartyl-glutamate. Brain Res 593: 140-143.
35. Meyerhoff JL, Koller KJ, Walczak DD, Coyle JT (1985). Regional brain levels of N-acetyl-aspartyl-glutamate: the effect of kindled seizures. Brain Res 346: 392-396.
36. Meyerhoff JL, Robinson MB, Bixler MA, Richards SS, Coyle JT (1989). Seizures decrease regional enzymatic hydrolysis of N-acetyl-aspartylglutamate in rat brain. Brain Res 505: 130-134.
37. Moffett JR, Cassidy M, Namboodiri MA (1989). Selective distribution of N-acetyl-aspartyl-glutamate immunoreactivity in the extrapyramidal system of the rat. Brain Res 494: 255-266.
38. Moghaddam B, Adams BW (1998). Reversal of phencydidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
39. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
40. Olney JW, Farber NB (1995). Glutamatergic receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998-1007.
41. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33: 523-533.
42. Passani LA, Vonsattel JP, Coyle JT (1997). Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res 772: 9-22.
43. Reuss B, Leung DS, Ohlemeyer C, Kettenmann H, Unsicker K (2000). Regionally distinct regulation of astroglial neurotransmitter receptors by fibroblast growth factor-2. Mol Cell Neurosci 16: 42-58.
44. Robinson MB, Blakely RD, Couto R, Coyle JT (1987). Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 262: 14498-14506.
45. Robinson MB, Blakely RD, Coyle JT (1986). Quisqualate selectively inhibits a brain peptidase which cleaves N-acetyl-L-aspartyl-L-glutamate in vitro. Eur J Pharmacol 130: 345-347.
46. Schipke CG, Ohlemeyer C, Matyash M, Nolte C, Kettenmann H, Kirchhoff F (2001). Astrocytes of the mouse neocortex express functional N-methyl-D-aspartate receptors. FASEB J 15: 1270-1272.
47. Sekiguchi M, Okamoto K, Sakai Y (1989). Low-concentration N-acetylaspartylglutamate suppresses the climbing fiber response of Purkinje cells in guinea pig cerebellar slices and the responses to excitatory amino acids of Xenopus laevis oocytes injected with cerebellar mRNA. Brain Res 482: 87-96.
48. Sharp FR, Butman M, Wang S, Koistinaho J, Graham SH, Sagar SM et al (1992). Haloperidol prevents induction of the hspa70 heat shock gene in neurons injured by phencyclidine (PCP), MK801, and ketamine. J Neurosci Res 33: 605-616.
49. Sharp JW, Petersen DL, Langford MT (1995). DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res 687: 114-124.
50. Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG (1998). Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci USA 95: 316-321.
51. Sigmundsson T, Suckling J, Maier M, Williams S, Bullmore E, Greenwood K et al (2001). Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry 158: 234-243.
52. Slusher BS, Robinson MB, Tsai G, Simmons ML, Richards SS et al (1990). Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. J Biol Chem 265: 21297-21301.
53. Slusher BS, Tsai G, Yoo G, Coyle JT (1992). Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Comp Neurol 315: 217-229.
54. Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, Bhardwaj A et al (1999). Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 5: 1396-1402.
55. Speno HS, Luthi-Carter R, Macias WL, Valentine SL, Joshi AR, Coyle JT (1999). Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol 55: 179-185.
56. Stauch BL, Robinson MB, Forloni G, Tsai G, Coyle JT (1989). The effects of N-acetylated alpha-linked acidic dipeptidase (NAALA-Dase) inhibitors on [3H]NAAG catabolism in vivo. Neurosci Lett 100: 295-300.
57. Tamminga CA (1998). Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12: 21-36.
58. Tsai G, Forloni G, Robinson MB, Stauch BL, Coyle JT (1993a). Calcium-dependent evoked release of N-[3H]acetylaspartyl-glutamate from the optic pathway. J Neurochem 51: 1956-1959.
59. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE et al (1995). Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52: 829-883.
60. Tsai G, Slusher BS, Sim L, Coyle JT (1993b). Immunocytochemical distribution of N-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. J Chem Neuroanat 6: 277-292.
61. Tsai G, Stauch BL, Vornov JJ, Deshpande JK, Coyle JT (1990). Selective release of N-acetylaspartylglutamate from rat optic nerve terminals in vivo. Brain Res 518: 313-316.
62. Tsai GC, Stauch-Slusher B, Sim L, Hedreen JC, Rothstein JD, Kuncl R et al (1991). Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. Brain Res 556: 151-156.
63. Weinberger DR, Berman KF, Suddath R, Torrey EF (1992). Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow studyof discordant monozygotic twins. Am J Psychiatry 149: 890-897.
64. Williamson LC, Neale JH (1988). Calcium-dependent release of N-acetylaspartylglutamate from retinal neurons upon depolarization. Brain Res 475: 151-155.
65. Wroblewska B, Wroblewski JT, Pshenichkin S, Surin A, Sullivan SE, Neale JH (1997). N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 69: 174-181.
66. Zanassi P, Paolillo M, Montecucco A, Avvedimento EV, Schinelli S (1999). Pharmacological and molecular evidence for dopamine D1 receptor expression by striatal astrocytes in culture. J Neurosci Res 58: 544-552.
67. Zollinger M, Amsler U, Brauchlitheotokis J, Gutteckamsler U, Do KQ, Streit P et al (1994). Release of N-acetylaspartylglutamate from slices of rat cerebellum, striatum and spinal cord, and the effect of climbing fiber deprivation. J Neurochem 63: 1133-1142.